BFH772

Item no.	HY-100419-5mg
Manufacturer	MedChem Express
CASRN	890128-81-1
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 1mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Bladder Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	96.25
Formula	C23H16F3N3O3
Citations	[1]Bold G, et al. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132-46.
Smiles	O=C(NC1=CC(C(F)(F)F)=CC=C1)C2=CC=CC3=CC(OC4=NC=NC(CO)=C4)=CC=C32
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	890128-81-1
Available
Product Description	BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	439.39
Clinical_Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturers Target	VEGFR
Isoform	VEGFR2/KDR/Flk-1
Pathway	Protein Tyrosine Kinase/RTK

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100419-5mg-safety-datasheet.pdf